177Lu-PNT6555

N/A

Report date: 2025/12/02 14:07:06
NME

Base Information

Drug Name177Lu-PNT6555
Drug Alias NamePNT-6555
ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionFibroblast activation protein alpha antagonistsIonising radiation emittersPositron-emission tomography enhancers +[4] 
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsSkin MelanomaSolid tumoursColorectal Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPoint Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesPoint Biopharma IncNew England Medical Center, Tufts University School Of Medicine
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsSkin MelanomaColorectal NeoplasmsEsophageal Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A